Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00380679|
Recruitment Status : Unknown
Verified September 2006 by Louisiana State University Health Sciences Center in New Orleans.
Recruitment status was: Active, not recruiting
First Posted : September 26, 2006
Last Update Posted : September 26, 2006
According to the Advisory Committee on Immunization Practices (ACIP), all people aged 50 years or older and persons aged less than 50 years who have medical conditions that put them at increased risk for serious influenza disease should receive an annual influenza vaccination. However, since the mid-1990s, vaccination rates and racial disparities have mostly remained static, and there has been limited progress towards the Healthy People 2010 objectives for influenza vaccination coverage.
The purpose of this study is to determine what proportion of previously unvaccinated persons in target groups for whom influenza and pneumococcal vaccine are recommended will accept and receive influenza and/or pneumococcal vaccine in an urban emergency department (ED), and to estimate the potential impact of ED vaccination on population-based vaccination coverage. The intervention will utilize a combination of assessment survey, vaccine information and pre-printed vaccine order sheets.
The target population for influenza vaccinations includes all patients aged 18 years and older for whom influenza vaccine is recommended by the ACIP. This includes all persons aged 50 years and older and persons aged 18 to 49 years who are in one of the following groups: 1) health care workers, 2) pregnant women, 3) residents of long-term care facilities, 4) household contacts and out-of-home caregivers of children aged 0 to 23 months, or 5) persons with underlying chronic medical conditions which increase their risk of influenza-related complications. The target population for pneumococcal vaccination includes all patients aged 65 years or older who have not previously been vaccinated against pneumococcus or have not received the vaccine within 5 years (and were less than 65 years at the time of vaccination).
|Condition or disease||Intervention/treatment||Phase|
|High Risk for Serious Influenza High Risk for Pneumonia||Biological: Influenza vaccination Biological: Pneumococcal polysaccharide vaccination||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department|
|Study Start Date :||December 2005|
|Study Completion Date :||March 2006|
- Acceptance of vaccinations
- Receipt of vaccination
- Reasons vaccines were refused
- Reasons vaccines were not administered
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00380679
|United States, Louisiana|
|Baton Rouge General Medical Center|
|Baton Rouge, Louisiana, United States, 70806|
|Our Lady of the Lake Regional Medical Center|
|Baton Rouge, Louisiana, United States, 70808|
|Principal Investigator:||William M Cassidy, MD||Louisiana State University Health Sciences Center|
|Principal Investigator:||Daniel Fishbein, MD||Centers for Disease Control and Prevention|